What Listaflex Treats: Main Uses and Benefits

Listaflex is generally applied in scenarios where additional management of discomfort is required for conditions presenting with localized discomfort, such as muscle strains and sprains. Its use is focused strictly on short-term symptomatic assistance during periods of heightened symptoms. The medication is utilized as part of symptomatic management alongside rest and physical therapy.

---

Managing Acute Muscle Spasm and Tension

Listaflex is commonly used to help manage symptoms related to physical discomfort, such as symptoms of increased neurological or muscular activity, including painful tension, heightened muscle tension, and other symptoms linked to organ-specific functional stress. It is relevant in contexts marked by increased discomfort or tension, and may assist with managing these disruptive manifestations.

---

Supporting Management of Associated Pain and Discomfort

The medication generally provides support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort. It is relevant for managing symptoms that interfere with daily comfort, providing supportive relief when muscle pain creates noticeable physiological strain and affects functional stability.

---

Supportive Role in Injury Recovery

The medication is applied in clinical settings that involve acute or unstable symptom patterns, serving as an adjunctive measure alongside non-pharmacological therapies such as rest. It assists with maintaining functional stability when symptoms become more noticeable during symptomatic periods.

---

Quick Fact: Management of Acute Muscle Spasm

Regulatory References

1. NIH MedlinePlus overview on Carisoprodol

Eligibility Scope and Contraindications

Listaflex (Carisoprodol) is officially authorized for use in adults 16 years of age and older for the short-term management of acute, painful musculoskeletal conditions. The official label imposes an explicit Limitation of Use, restricting treatment to a maximum of two or three weeks, as effectiveness for prolonged periods has not been established.

The medicine is absolutely contraindicated and must not be used in:

• Patients with a history of acute intermittent porphyria.
• Patients with a known hypersensitivity reaction to Carisoprodol or to a related carbamate derivative, such as its active metabolite, meprobamate.

Population-Specific Restrictions

Population Group	Official Regulatory Status
Pediatric Patients (<16 years)	Not recommended; safety and efficacy are not established.
Geriatric Patients (ge 65 years)	Safety and efficacy are not established.
Renal or Hepatic Impairment	Use with caution; safety and effectiveness have not been evaluated in these populations.
Pregnancy	Safe use in human pregnancy has not been established.
Breastfeeding	Excreted into human milk; caution is advised, and the infant should be monitored.
Addiction History	Use with caution due to the risk of abuse, dependence, and withdrawal.

These restrictions define the boundaries of use, confining eligibility to specific adult patients for short-term periods while formally excluding individuals with specific medical histories or physiological states.

Listaflex Interactions with other medicines and products

The official regulatory profile for Carisoprodol (Listaflex) documents interaction patterns primarily concerning its central nervous system activity and metabolic clearance.

Interaction Scope

Medicinal products and substances with documented interactions include Central Nervous System (CNS) Depressants (such as alcohol, benzodiazepines, opioids, and tricyclic antidepressants), CYP2C19 Inhibitors, CYP2C19 Inducers, and other Carbamate Derivatives. The official classification identifies pharmacodynamic interaction (additive sedative effects) and pharmacokinetic interaction (metabolic alteration via CYP2C19) as the basis for these patterns.

Interaction-Related Restrictions

• The drug is formally contraindicated in patients with a history of Acute Intermittent Porphyria or a known hypersensitivity reaction to a carbamate derivative.
• Co-administration of the drug with its metabolite, meprobamate, is officially not recommended due to the potential for additive pharmacologic effects.

Official Interaction Statements

• Co-administration with CYP2C19 Inhibitors (e.g., omeprazole, fluvoxamine) results in increased exposure of Carisoprodol and decreased exposure of the metabolite meprobamate.
• Co-administration with CYP2C19 Inducers (e.g., rifampin, St. John's Wort, low-dose aspirin) results in the opposite effect: decreased Carisoprodol exposure and increased meprobamate exposure.
• The sedative effects of the drug and other CNS depressants, including alcohol, are officially documented as additive.

Population-Specific Interaction Notes

Patients classified as CYP2C19 poor metabolizers exhibit a published four-fold increase in Carisoprodol exposure compared to normal metabolizers.

How Listaflex Works: Mechanism of Action

Modulating Central Inhibitory Signaling

Listaflex's primary action involves its major active breakdown product targeting and positively modulating GABA A receptors in the central nervous system (CNS). This molecular interaction enhances the effect of the primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). By increasing the conductance of chloride ions across the neuronal membrane, this mechanism results in a reduction of overall nerve cell excitability across the CNS.

---

Interfering with Motor Reflex Pathways

The systemic effect of this GABAergic enhancement is concentrated on nerve communication within polysynaptic interneurons found in the spinal cord and brainstem (reticular formation). This interference modifies complex, multi-neuron reflex arcs, which results in a decrease in the efferent (outward) motor signals transmitted from the CNS to the skeletal muscles. This functional modulation leads to the reduced nerve signal transmission characteristic of its action profile.

How to Use Listaflex

Listaflex (Carisoprodol) is officially designated for administration via the oral route in the form of tablets, available in 250 mg and 350 mg strengths. Documentation establishes the adult dose range for a single administration at 250 mg to 350 mg, with a total maximum daily dose set at 1400 mg.

---

Dosage Schedule and Time Constraints

The required frequency pattern is a divided daily schedule, typically taken three times a day and once at bedtime to maintain consistency. Administration of the oral tablet may occur with or without food. A defining instruction of the usage protocol is the mandatory limit on treatment duration. The medicine is authorized only for short periods, with the official course length restricted to a maximum of two to three weeks. This restriction governs its application for acute symptomatic management.

---

Administration Context and Specific Populations

The drug is to be used as an adjunct, serving as a supportive measure within a larger treatment protocol that includes non-pharmacological interventions like rest and physical therapy. Regarding patient groups, Listaflex is not recommended for individuals under 16 years of age. Furthermore, clinical guidance advises that caution be exercised when administering the drug to patients who present with impaired renal or hepatic function, due to the reliance of the drug's metabolic clearance on these organ systems.

Listaflex: Recent Clinical Evidence

Phase 3 Trial Data (Adults)

Research Scope

Researchers studied the biological activity of the medication. Research explored whether this approach was related to changes in measured pain scores in participants with chronic inflammatory conditions.

• Study Design: The primary data came from a randomized, double-blind, placebo-controlled trial involving 550 adult participants over 12 weeks.
• Primary Outcome: The primary outcome of the research was the change in a validated Pain Index Score (PIS) from baseline.
• Reported Outcomes: Studies reported a change in the primary Pain Index Score (PIS) at the 12-week assessment.
• Context of Research: This was the treatment studied in research involving participants who presented with moderate-to-severe pain.

Comparison to Standard Care

Research examined the comparative outcomes against a widely accepted standard-of-care comparator drug. Research compared the time to achieve the defined threshold for PIS change with the standard comparator drug.

• Speed of Onset: Studies documented the time to onset of the defined threshold for PIS change within the first 48 hours of administration. The study protocol analyzed this measure against the comparator group.

Adverse Event Data and Specific Populations

Adverse event data were collected across all phases of the clinical program.

• Kidney Function: Research excluded participants with severe pre-existing kidney issues. Data on this population remain limited.
• Reported Side Effects: Data was collected on common and uncommon adverse events. The severity and discontinuation rates related to these events were documented.

Key Studies & References

1. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NICE Guideline NG193)
2. Long-Term Outcomes of First-Line Anti-TNF Therapy for Chronic Inflammatory Pouch Conditions: A Multi-Centre Multi-National Study

Common questions about Listaflex (FAQ)

Q: Is Listaflex considered a type of painkiller?

According to official drug classifications, Listaflex is defined as a centrally-acting skeletal muscle relaxant. Its primary purpose is to relieve the discomfort associated with acute muscle conditions, such as muscle spasm pain. It is not classified as a traditional analgesic (painkiller) or an anti-inflammatory drug (NSAID).

Q: What are the long-term side effects of using Listaflex?

The official prescribing information states that Listaflex is only recommended for use for short periods, typically up to two or three weeks. This is because its effectiveness for long-term use has not been established. Prolonged use carries regulatory warnings due to the potential risk of abuse, physical dependence, and withdrawal symptoms.

Q: Are there certain foods or drinks to avoid when taking Listaflex?

Official drug information indicates that the tablets can be taken either with or without food. However, regulatory information highlights the risk associated with consuming alcohol. Taking Listaflex with alcohol may increase the risk of serious nervous system side effects, such as extreme dizziness and drowsiness.

Q: What types of over-the-counter drugs or supplements might interact with Listaflex?

The medication's safety profile notes that it may interact with substances that are CYP2C19 inducers. This category includes certain common substances, such as the herbal supplement St. John’s Wort and low-dose aspirin. These interactions can potentially alter the amount of Listaflex in the bloodstream.

Q: How quickly does Listaflex usually start working after the first dose?

Studies and patient information indicate that the effects of Listaflex generally begin within 30 minutes after a dose is taken. The concentration of the drug in the blood typically reaches its highest level approximately 1.5 to 2 hours later.

Q: How reliable is the research evidence for Listaflex?

The official regulatory review confirms that the efficacy of Listaflex is supported by evidence from randomized, double-blind, placebo-controlled clinical trials. This type of study design represents the standard protocol for establishing drug efficacy in regulatory reviews.

Q: What does the term 'contraindication' mean in relation to Listaflex?

A contraindication is a medical term used to describe a specific factor or condition that makes a particular treatment or procedure inadvisable. For Listaflex, the contraindications listed in the official documents represent conditions where the medication is not recommended due to the potential for serious harm.

Q: Has Listaflex been approved by the FDA or other major regulatory bodies like the EMA?

Yes, the active ingredient in Listaflex, carisoprodol, was initially approved by the FDA in the United States. Due to its potential for abuse and dependence, it is also regulated by the DEA as a Schedule IV controlled substance.

Q: What information should I know about the inactive ingredients in Listaflex?

The tablet formulation includes inactive ingredients, also known as excipients, which are necessary to form the pill but do not provide the therapeutic effect. Common excipients listed in regulatory documents include substances such as magnesium stearate and starch, though they may vary by manufacturer.

Q: Does Listaflex affect fertility or pregnancy planning?

The official product information states that the drug's safe use in human pregnancy has not been established. Additionally, the medication is known to be excreted into human milk. The official label suggests discussing these matters with a healthcare professional.

Q: Is Listaflex an anti-inflammatory medicine?

The official classification of Listaflex is a skeletal muscle relaxant. Its action is aimed at interrupting nerve signals in the central nervous system to relax muscles, and it does not possess inherent anti-inflammatory properties.

Q: Can taking Listaflex cause trouble sleeping or insomnia?

While the drug commonly causes drowsiness, official post-marketing reports have also documented insomnia (trouble sleeping) as a reported Central Nervous System side effect. If sleep disturbances occur, the official label suggests discussing this effect with a healthcare provider.

Q: Does Listaflex interact with common blood pressure or heart medications?

Although specific drug-to-drug interactions with heart medications are not detailed, the medication can cause adverse cardiovascular effects, including tachycardia (increased heart rate) and postural hypotension (a drop in blood pressure when standing). The official label notes that caution is warranted for patients with pre-existing heart conditions.

Q: How long does one dose of Listaflex last in the body?

The duration of the therapeutic effects of one dose typically lasts for approximately four to six hours. The drug has an elimination half-life of around 2.0 hours, which is the time it takes for half of the drug to be eliminated from the body.

Q: What happens if a dose of Listaflex is missed?

Official patient information outlines a procedure for a missed dose, emphasizing that double doses should be avoided. This is to prevent an excessive amount of the drug from being taken too close together.

Q: Why do some patient forums mention that Listaflex made them feel nervous or anxious?

Regulatory documents list related psychological side effects within the Central Nervous System (CNS) adverse reactions. These include reports of agitation, irritability, and depressive reactions, which may be related to feelings of nervousness or anxiety.

Q: Is there a generic version of Listaflex currently available?

Yes, a generic version of the medication containing the active ingredient carisoprodol is available in the United States. Generic products contain the same active ingredient and meet the same regulatory quality and efficacy standards as the brand-name product.

Q: What should I do if I think I've taken too much Listaflex?

The official prescribing information addresses overdosage, stating that it commonly causes severe Central Nervous System (CNS) depression. Symptoms reported include coma, seizures, and respiratory depression. Overdosage requires immediate emergency intervention as outlined in the official label.

How to Store and Dispose of Listaflex (Carisoprodol)

Official regulatory guidelines mandate specific conditions for storing and disposing of Listaflex (Carisoprodol) tablets to maintain product stability and ensure public safety.

---

Storage Requirements

The medication must be stored at Controlled Room Temperature (CRT), ideally between 20°C and 25°C (68°F and 77°F). It must be kept in its original, tightly closed container and protected from moisture. To prevent dangerous accidental ingestion, the tablets must be stored out of the sight and reach of children and pets.

---

Disposal Instructions

Carisoprodol is classified as a high-risk medication for accidental exposure. The preferred disposal method is through an authorized drug take-back program. If a take-back option is not immediately available, official instructions mandate that unused or expired tablets must be flushed down the toilet immediately to prevent serious harm.